Cohort 2 patients
Sixty-five patients with relapsed or persistent disease (mean age, 52.5 ± 11.0 y; range, 18–74 y) were enrolled. Patients’ baseline characteristics are shown in Table S1 . Of those treated with various chemotherapy regimens, 39 (60.0%) received adjuvant platinum-based chemotherapy and 22 (33.8%) had prior BEV use. BEV dosage was 7.0–12.6 (mean, 9.5 ± 1.3) mg/kg and 7.9–11.6 (mean, 10.2 ± 1.1) mg/kg for patients with the first and ≥2 relapses, respectively; the number of treatment cycles was 1–22 (mean 5.3 ± 3.1) and 2–19 (mean 6.5 ± 4.4), respectively. The median follow-up period was 3.6 m (range 0.1–37.3 m). Most patients (n=60, 92.3%) were diagnosed with EOC; 2 (3.1%) and 3 (4.6%) were diagnosed with TC and PPC, respectively. Thirty-nine patients (60.0%) had serous histology, 10 (15.4%) had CCC histology, 6 (9.2%) had endometrioid histology, and 4 (6.2%) had mucinous histology. During follow-up, 39 patients (60.0%) developed progressive disease, and 29 (44.86%) died.
Relationships between PFI <6 or ≥6 m and clinicopathological factors are presented in Table S1 . No statistical difference between PFI of 6 m and stage, histology, tumour grade, residual tumour size during primary surgery, or next disease progression was observed.